Increasing telmisartan vs amlodipine dose in patients with hypertension, type 2 diabetes and microalbuminuria
Julia Lewis
Correspondence Division of Nephrology, Vanderbilt University, Medical Center, S-3223 Medical Center North Nashville, TN 37232–2372 USA
Email julia.lewis@vanderbilt.edu
This article has no abstract so we have provided the first paragraph of the full text.
In patients with type 2 diabetes, hypertension, and microalbuminuria or proteinuria, treatment with ARBs has been conclusively shown to reduce albuminuria and preserve renal function.1, 2, 3 Since the publication of the landmark trials that demonstrated these benefits, several small studies have found that ARBs reduce UAE to an even greater extent when administered at doses above those necessary or recommended by the FDA for blood pressure control.4, 5 The study by Fogari et al. adds more evidence to support the use of ARBs at higher doses, by demonstrating that further reductions in UAE can be obtained by increasing doses of the ARB telmisartan to 160 mg/day. Importantly, the authors did not find increased rates of adverse events, such as symptomatic hypotension or hyperkalemia, with the increased telmisartan doses.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
